Transplant-related features of patients classified according to WHO criteria
| Transplant timing . | MDS (n = 374) . | Oligoblastic AML (n = 145) . | Comparison between MDS and oligoblastic AML, P . |
|---|---|---|---|
| Time from diagnosis to allogeneic HSCT | 9.5 (1-189.3) | 8.3 (1-15.2) | NS |
| Type of donor | |||
| Sibling | 232 (62%) | 98 (66%) | NS |
| Unrelated donor (MUD)* | 142 (38%) | 47 (34%) | |
| Source of hematopoietic stem cells | |||
| Peripheral blood/cord blood | 239 (64%) | 67 (54%) | .02 |
| Bone marrow | 135 (36%) | 58 (46%) | |
| Remission-induction chemotherapy† | 112 (30%) | 128 (88%) | <.001 |
| Complete remission achieved | 58 (52%) | 56 (44%) | NS |
| Conditioning regimen‡ | |||
| Standard conditioning regimen | 236 (63%) | 96 (66%) | NS |
| Reduced-intensity conditioning | 138 (37%) | 49 (34%) |
| Transplant timing . | MDS (n = 374) . | Oligoblastic AML (n = 145) . | Comparison between MDS and oligoblastic AML, P . |
|---|---|---|---|
| Time from diagnosis to allogeneic HSCT | 9.5 (1-189.3) | 8.3 (1-15.2) | NS |
| Type of donor | |||
| Sibling | 232 (62%) | 98 (66%) | NS |
| Unrelated donor (MUD)* | 142 (38%) | 47 (34%) | |
| Source of hematopoietic stem cells | |||
| Peripheral blood/cord blood | 239 (64%) | 67 (54%) | .02 |
| Bone marrow | 135 (36%) | 58 (46%) | |
| Remission-induction chemotherapy† | 112 (30%) | 128 (88%) | <.001 |
| Complete remission achieved | 58 (52%) | 56 (44%) | NS |
| Conditioning regimen‡ | |||
| Standard conditioning regimen | 236 (63%) | 96 (66%) | NS |
| Reduced-intensity conditioning | 138 (37%) | 49 (34%) |
Criteria for selection of HLA-MUDs before 2002 included low-resolution typing for HLA class I (A and B) and high-resolution typing for HLA-DRB1. Since 2002, criteria included high-resolution typing for both HLA class I (A, B, and C) and class II alleles (DRB1/3/4/5, DQA1, DPB1).
Treatments other than induction chemotherapy included hypomethylating agents (39 patients, 8%), lenalidomide, and immunosuppressive agents (13 patients, 3%).
For patients receiving standard conditioning, most frequent conditioning regimens included the following: busulphan and cyclophosphamide (33% of cases), and total body irradiation and cyclophosphamide (29%). For patients receiving reduced-intensity conditioning, most frequent conditioning regimens included the following ones: thiotepa and fludarabine (31% of cases), thiotepa and cyclophosphamide (30%), and nonablative total body irradiation and fludarabine (24%). For most patients, graft-versus-host disease prophylaxis was based on combined use of cyclosporine and methotrexate.